"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 7 | 19 | 26 |
| 1996 | 9 | 21 | 30 |
| 1997 | 5 | 17 | 22 |
| 1998 | 4 | 19 | 23 |
| 1999 | 9 | 16 | 25 |
| 2000 | 10 | 25 | 35 |
| 2001 | 12 | 29 | 41 |
| 2002 | 13 | 34 | 47 |
| 2003 | 16 | 25 | 41 |
| 2004 | 14 | 29 | 43 |
| 2005 | 10 | 34 | 44 |
| 2006 | 11 | 32 | 43 |
| 2007 | 8 | 25 | 33 |
| 2008 | 10 | 41 | 51 |
| 2009 | 12 | 36 | 48 |
| 2010 | 11 | 41 | 52 |
| 2011 | 6 | 35 | 41 |
| 2012 | 8 | 27 | 35 |
| 2013 | 7 | 39 | 46 |
| 2014 | 6 | 44 | 50 |
| 2015 | 10 | 45 | 55 |
| 2016 | 14 | 26 | 40 |
| 2017 | 10 | 31 | 41 |
| 2018 | 6 | 38 | 44 |
| 2019 | 10 | 22 | 32 |
| 2020 | 7 | 28 | 35 |
| 2021 | 5 | 24 | 29 |
| 2022 | 1 | 20 | 21 |
| 2023 | 3 | 20 | 23 |
| 2024 | 7 | 12 | 19 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Treatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies. Cancer. 2025 Jan 15; 131(2):e35713.
-
Inosine monophosphate dehydrogenase 2 (IMPDH2) modulates response to therapy and chemo-resistance in triple negative breast cancer. Sci Rep. 2025 Jan 07; 15(1):1061.
-
Real-world data on the clinical features, therapy patterns, and outcomes of older adults with diffuse large B-cell lymphoma in Latin America: A study from the Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL). J Geriatr Oncol. 2025 Jan; 16(1):102160.
-
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas. Neuro Oncol. 2024 Nov 04; 26(11):2044-2060.
-
Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors. Clin Genitourin Cancer. 2024 Dec; 22(6):102242.
-
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med. 2024 Oct 17; 391(15):1379-1389.
-
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun. 2024 10 01; 4(10):2823-2834.
-
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 2024 Dec; 38(12):2717-2721.
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
-
T-Cell-Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features. Arch Pathol Lab Med. 2024 Aug 01; 148(8):914-920.